Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Blood (2024) 144 (14): 1486–1495.

https://doi.org/10.1182/blood.2023023780

Published: 2024

Includes: Supplemental data

Journal Articles

Neonatal Exchange Transfusion: When Should We Think about Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)?

Erika Tarasco, Kenneth D. Friedman, James N. George, Paul Knöbl, Ingrid Hrachovinova, Masanori Matsumoto, Reinhard Schneppenheim, Anne Sophie Von Krogh, Bernhard Lammle, Johanna A. Kremer Hovinga Strebel

Blood (2022) 140 (Supplement 1): 336–337.

https://doi.org/10.1182/blood-2022-168612

Published: 2022

Journal Articles

Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies

Irene Graf, Georg Greiner, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knöbl, Alexander Hauswirth, Manja Meggendorfer, Ulrich Jaeger, Constance Baer, Torsten Haferlach, Gregor Hoermann, Peter Valent, Wolfgang R. Sperr

Blood (2022) 140 (Supplement 1): 11634–11635.

https://doi.org/10.1182/blood-2022-162588

Published: 2022

Journal Articles

Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Lucas Kühne, Dennis A. Eichenauer, Paul Knöbl, Linus A. Völker, Jessica Kaufeld, Ralph Wendt, Holger Hägele, Thomas Osterholt, Marcus Bieringer, Veronika Buxhofer-Ausch, Jan Menne, Ulf Schoenermarck, Paul Brinkkoetter

Blood (2021) 138 (Supplement 1): 2087.

https://doi.org/10.1182/blood-2021-151283

Published: 2021

Journal Articles

Caplacizumab Is Effective in Treating Immune-Mediated Thrombotic Thrombocytopenic Purpura in Real-World Scenarios and May Lower Mortality: An Aggregative Analysis

Linus A. Völker, Gesa Balduin, Lucas Kühne, Jessica Kaufeld, Ulf Schönermarck, Jan Menne, Paul Knöbl, Paul Brinkkoetter

Blood (2021) 138 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2021-153211

Published: 2021

Journal Articles

Long-Term Renal Outcomes in Hereditary TTP Patients: Data from the International Hereditary TTP Registry

Erika Tarasco, Ralph Wendt, Anne Sophie von Krogh, Sibylle Tschumi, James N. George, Masanori Matsumoto, Paul Knöbl, Reinhard Schneppenheim, Bernhard Lämmle, other members of Hereditary TTP Registry Steering Committee, Johanna A. Kremer Hovinga Strebel

Blood (2021) 138 (Supplement 1): 770.

https://doi.org/10.1182/blood-2021-146128

Published: 2021

Journal Articles

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

Katharina Holstein, Xiaofei Liu, Andrea Smith, Paul Knöbl, Robert Klamroth, Ulrich Geisen, Hermann Eichler, Wolfgang Miesbach, Andreas Tiede

Blood (2020) 136 (3): 279–287.

https://doi.org/10.1182/blood.2019003639

Published: 2020

Includes: Supplemental data

Journal Articles

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Johanna A. Kremer Hovinga, MD Prof, Marie Scully, MD MRCP, FRCPath, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD, Ara Metjian, MD

Blood (2018) 132 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2018-99-112177

Published: 2018

Journal Articles

Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients

Anette Anette Van Dorland, PhD, Magnus Mansouri Taleghani, MD, Kenneth Dale Friedman, MD, James George, MD, Ingrid Hrachovinova, PhD, Paul Knöbl, MD PhD, Bernhard Lammle, MD, Masanori Matsumoto, MD, Anne Sophie von Krogh, MD, Reinhard Schneppenheim, MDPhD, Isabella Aebi-Huber, Bütikofer Lukas, PhD, Zuzana Cermakova, PhD, Petter Quist-Paulsen, MD PhD, Deirdra Terrell, PhD, Sara K. Vesely, PhD MPH, Yoshihiro Fujimura, MD PhD, Johanna A. Kremer Hovinga Strebel, MD

Blood (2018) 132 (Supplement 1): 376.

https://doi.org/10.1182/blood-2018-99-112095

Published: 2018

Journal Articles

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Flora Peyvandi, MD PhD, Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 373.

https://doi.org/10.1182/blood-2018-99-112125

Published: 2018

Journal Articles

Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Paul Knöbl, MD PhD, Marie Scully, MD MRCP, FRCPath, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 3739.

https://doi.org/10.1182/blood-2018-99-112174

Published: 2018

Journal Articles

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 1142.

https://doi.org/10.1182/blood-2018-99-112179

Published: 2018

Journal Articles

Concizumab (Anti-TFPI) Exposure-Response Modeling in Patients with Hemophilia A

Hermann Eichler, MD, Pantep Angchaisuksiri, MD, Kaan Kavakli, MD, Paul Knöbl, MD PhD, Jerzy Windyga, Victor Jimenez-Yuste, Ute Friedrich, PhD, Philip Delff Andersen, Pratima Chowdary

Blood (2017) 130 (Supplement 1): 3672.

https://doi.org/10.1182/blood.V130.Suppl_1.3672.3672

Published: 2017

Journal Articles

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Tea Pemovska, PhD, Gregory Ian Vladimer, PhD, Vitaly Sedlyarov, PhD, Emir Hadzijusufovic, DVM, Karoline Veronika Gleixner, MD, Alexandra Keller, MSc, Berend Snijder, PhD, Nikolaus Krall, PhD, Oscar Lopez de la Fuente, BSc, Mathias A Schneeweiss, MD, Wolfgang R. Sperr, MD, Paul Knöbl, MD PhD, Klaus Geissler, MD, Philipp Bernhard Staber, MD PhD, Ulrich Jaeger, MD, Peter Valent, MD, Giulio Superti Furga, PhD

Blood (2017) 130 (Supplement 1): 4227.

https://doi.org/10.1182/blood.V130.Suppl_1.4227.4227

Published: 2017

Journal Articles

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Marie Scully, MD, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD, Ara Metjian, MD, Javier de la Rubia, MD, Katerina Pavenski, MD, Filip Callewaert, PhD, Debjit Biswas, PhD, Hilde De Winter, MD, Robert K. Zeldin, MD

Blood (2017) 130 (Supplement 1): LBA-1.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-1.LBA-1

Published: 2017

Journal Articles

Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study

Katharina Holstein, MD, Andrea Smith, Paul Knöbl, MD PhD, Christiane Dobbelstein, MD, Wolfgang A. Miesbach, MD PhD, Michael Spannagl, MD PhD, Jürgen Heinz, MD PhD, Ute Scholz, MD, Hermann Eichler, MD, Angela Huth-Kühne, MD, Robert Klamroth, MD PhD, Armin Koch, MD PhD, Andreas Tiede, MD

Blood (2017) 130 (Supplement 1): 22.

https://doi.org/10.1182/blood.V130.Suppl_1.22.22

Published: 2017

Journal Articles

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

Marie Scully, Paul Knöbl, Karim Kentouche, Lawrence Rice, Jerzy Windyga, Reinhard Schneppenheim, Johanna A. Kremer Hovinga, Michiko Kajiwara, Yoshihiro Fujimura, Caterina Maggiore, Jennifer Doralt, Christopher Hibbard, Leah Martell, Bruce Ewenstein

Blood (2017) 130 (19): 2055–2063.

https://doi.org/10.1182/blood-2017-06-788026

Published: 2017

Includes: Supplemental data

Journal Articles

Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation

Blood (2016) 128 (22): 3189.

https://doi.org/10.1182/blood.V128.22.3189.3189

Published: 2016

Journal Articles

High Spontaneous In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia is Associated with Mutations in Rasopathy Genes, Myeloproliferation and Inferior Prognosis

Blood (2016) 128 (22): 5503.

https://doi.org/10.1182/blood.V128.22.5503.5503

Published: 2016

Journal Articles

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Andreas Tiede, Christoph J. Hofbauer, Sonja Werwitzke, Paul Knöbl, Saskia Gottstein, Rüdiger E. Scharf, Jürgen Heinz, Jürgen Groß, Katharina Holstein, Christiane Dobbelstein, Fritz Scheiflinger, Armin Koch, Birgit M. Reipert

Blood (2016) 127 (19): 2289–2297.

https://doi.org/10.1182/blood-2015-09-672774

Published: 2016

Includes: Supplemental data

NARROW

Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Neonatal Exchange Transfusion: When Should We Think about Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)?

Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies

Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Caplacizumab Is Effective in Treating Immune-Mediated Thrombotic Thrombocytopenic Purpura in Real-World Scenarios and May Lower Mortality: An Aggregative Analysis

Long-Term Renal Outcomes in Hereditary TTP Patients: Data from the International Hereditary TTP Registry

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Concizumab (Anti-TFPI) Exposure-Response Modeling in Patients with Hemophilia A

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation

High Spontaneous In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia is Associated with Mutations in Rasopathy Genes, Myeloproliferation and Inferior Prognosis

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only